SolaranRx,
Inc., which is developing a peptide-based technology for treating
metastatic melanoma, is among the featured presenters at Biotech
Showcase™, January 12-14 in San Francisco. SolaranRx’s lead product,
SRX-1177, was recently selected among the 2014 Top 10 Most
Interesting Oncology Projects to Watch by Informa and Kantar Health
for its strong science and potential to address unmet medical needs in
treating metastatic melanoma.
Biotech Showcase™ is an investor and partnering conference that provides
private and public biotechnology and life sciences companies with an
opportunity to present to and meet with investors and pharmaceutical
executives in one place during the course of one of the industry's
largest annual healthcare investor conferences. Investors and
biopharmaceutical executives from around the world gather in San
Francisco during this critical week widely viewed as setting the tone
for the coming year. Last year’s event attracted more than 1,700
attendees.
SolaranRx’s lead product, SRX-1177, is a novel peptide linked to a
radioisotope that preferentially attaches to melanocortin-1 (MC1)
receptors, which are over-expressed in about 80 percent of melanoma
cells. SRX-1177 can be used to identify melanoma patients with MC1
receptors. Those patients can then be injected with therapeutic doses of
SRX-1177 to deliver targeted radiation to cancer cells, while minimizing
the impact on healthy cells. This merger of therapy and diagnostics
creates a unique theranostic product for metastatic melanoma.
“We are pleased to present our distinctive technology for treating
metastatic melanoma at Biotech Showcase,” said SolaranRx CEO Les
Stewart. “This is a deadly disease and physicians have few treatment
options. Current treatments for metastatic melanoma are ineffective for
a significant number of patients, have serious, sometimes fatal side
effects, and are costly to the healthcare system. Our peptide-based
technology has the potential to offer physicians a new therapeutic
option with fewer side effects for these patients.”
About SolaranRx, Inc.
SolaranRx, Inc. is developing a platform of new therapies and companion
imaging agents for the treatment of metastatic melanoma. This merger
between therapeutics and diagnostics—often referred to as
theranostics—constitutes a new level of personalized medicine for
treating metastatic melanoma. SolaranRx seeks to improve treatment and
patients’ quality of life, giving new options to clinicians and hope to
patients. Visit www.SolaranRx.com.
Copyright Business Wire 2015